Back to results
US 2025/0085286 A1Published application
Collagen Type XXII Assay
AssigneeNordic Biioscience A/S
InventorsEmilie Albrecht Madsen, Jeppe Thorlacius-Ussing, Nicholas Willumsen, Morten Asser Karsdal
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunoassays, in particular immunoassays for detecting and/or monitoring cancer in a patient, and to monoclonal antibodies and immunoassay kits for use in carrying out the immunoassays.
Claims19
1:
- A method of immunoassay for detecting and/or monitoring cancer in a patient, the method comprising:
- i) contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1);
- and
- ii) detecting and determining the amount of binding between said monoclonal antibody and peptides in the sample.
1 more element
2:
- The method of claim 1, wherein the method further comprises:
- iii) correlating said amount of binding of said monoclonal antibody as determined in step (ii) with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from said patient at a previous time point, and/or with a predetermined cut-off value.
3:
- The method of claim 1, wherein the cancer is bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, or stomach cancer.
4:
- The method of claim 1, wherein the cancer is pancreatic cancer.
5:
- The method of claim 4 further comprising providing a prognosis of overall survival, wherein an amount of binding of said monoclonal antibody as determined in step (ii) above the median value associated with known pancreatic cancer patients is associated with poor overall survival.
6:
- The method of claim 1, wherein the monoclonal antibody does not specifically bind to an elongated version of said C-terminus amino acid sequence which is AARPGNVKGPA (SEQ ID No. 3).
7:
- The method of claim 1, wherein the monoclonal antibody does not specifically bind to a truncated version of said C-terminus amino acid sequence which is AARPGNVKG (SEQ ID No. 4).
8:
- The method of claim 1, wherein the monoclonal antibody is raised against a synthetic peptide having the C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1).
9:
- The method of claim 1, wherein the sample is a biofluid sample selected from blood, serum or plasma.
10:
- The method of claim 1, wherein the immunoassay is a competition assay or a sandwich assay.
11:
- The method of claim 1, wherein the immunoassay is a radio-immunoassay or an enzyme-linked immunosorbent assay.
12:
- An immunoassay kit comprising a monoclonal antibody that specifically binds to a C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1), and at least one of;
- a streptavidin coated well plate;
- a biotinylated peptide Biotin-L-AARPGNVKGP (SEQ ID No. 15), wherein L is an optional linker;
- a secondary antibody for use in a sandwich immunoassay;
- a calibrator protein comprising the C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1);
- an antibody biotinylation kit;
- an antibody HRP labelling kit;
- an antibody radiolabelling kit;
- or
- an assay visualisation kit.
7 more elements
13:
- The immunoassay kit of claim 12, wherein the monoclonal antibody does not specifically bind to an elongated version of said C-terminus amino acid sequence which is AARPGNVKGPA (SEQ ID No. 3).
14:
- The immunoassay kit of claim 12, wherein the monoclonal antibody does not specifically bind to a truncated version of said C-terminus amino acid sequence which is AARPGNVKG (SEQ ID No. 4).
15:
- The immunoassay kit of claim 12, wherein the monoclonal antibody is raised against a synthetic peptide having the C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1).
16:
- A monoclonal antibody that specifically binds to a C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1).
17:
- The monoclonal antibody of claim 16, wherein the monoclonal antibody does not specifically bind to an elongated version of said C-terminus amino acid sequence which is AARPGNVKGPA (SEQ ID No. 3).
18:
- The monoclonal antibody of claim 16, wherein the monoclonal antibody does not specifically bind to a truncated version of said C-terminus amino acid sequence which is AARPGNVKG (SEQ ID No. 4).
19:
- The monoclonal antibody of claim 16, wherein the monoclonal antibody is raised against a synthetic peptide having the C-terminus amino acid sequence AARPGNVKGP (SEQ ID No. 1).